Abstract
Julien Haroche has shown how the discovery of abnormalities in the MAP kinase pathway has revolutionized our understanding of the pathophysiology of LCH and a related disease : Erdheim-Chester syndrome. He reported on the very encouraging results of treatment of these conditions with inhibitors of the MAP kinase pathway.
